![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ASML Holding NV (NASDAQ:ASML) – Semiconductor stocks rose globally after news that the US will exempt chipmakers in Japan, the Netherlands, and South Korea from new export restrictions...
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024...
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical and...
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2...
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0453 | -0.138849297938 | 32.6253 | 32.64 | 32.07 | 68152 | 32.31749746 | SP |
4 | 0.15 | 0.462534690102 | 32.43 | 32.9 | 32.07 | 152672 | 32.67921122 | SP |
12 | 0.69 | 2.16368767639 | 31.89 | 32.9 | 31.89 | 62659 | 32.60483954 | SP |
26 | 1.6 | 5.16462233699 | 30.98 | 32.9 | 30.82 | 33296 | 32.44842669 | SP |
52 | 3.3 | 11.2704918033 | 29.28 | 32.9 | 27.72 | 27836 | 31.15957724 | SP |
156 | 6.6502 | 25.6469390431 | 25.9298 | 32.9 | 23.59 | 19543 | 28.89532903 | SP |
260 | 6.77 | 26.2301433553 | 25.81 | 32.9 | 23.59 | 19454 | 28.8217681 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions